Gyre Therapeutics (GYRE) Competitors

Gyre Therapeutics (NASDAQ:GYRE) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Does the media refer more to GYRE or OGN?

In the previous week, Organon & Co. had 16 more articles in the media than Gyre Therapeutics. MarketBeat recorded 21 mentions for Organon & Co. and 5 mentions for Gyre Therapeutics. Organon & Co.'s average media sentiment score of 0.64 beat Gyre Therapeutics' score of 0.28 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GYRE or OGN more profitable?

Organon & Co. has a net margin of 13.49% compared to Gyre Therapeutics' net margin of -84.57%. Organon & Co.'s return on equity of 431.62% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-84.57%	-118.43%	-71.97%
Organon & Co.	13.49%	431.62%	8.03%

Do analysts recommend GYRE or OGN?

Organon & Co. has a consensus target price of $20.60, indicating a potential upside of 86.17%. Given Organon & Co.'s higher probable upside, analysts plainly believe Organon & Co. is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Organon & Co.	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Do insiders and institutionals have more ownership in GYRE or OGN?

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 19.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 1.4% of Organon & Co. shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer GYRE or OGN?

Organon & Co. received 17 more outperform votes than Gyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Gyre Therapeutics an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.

Company	Underperform	Outperform
Gyre Therapeutics	Outperform Votes 1 100.00%	Underperform Votes No Votes
Organon & Co.	Outperform Votes 18 33.33%	Underperform Votes 36 66.67%

Which has stronger valuation & earnings, GYRE or OGN?

Organon & Co. has higher revenue and earnings than Gyre Therapeutics. Organon & Co. is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$105.76M	7.44	-$92.93M	$0.05	168.00
Organon & Co.	$6.40B	0.45	$864M	$3.33	3.32

Which has more volatility & risk, GYRE or OGN?

Gyre Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

Organon & Co. beats Gyre Therapeutics on 13 of the 19 factors compared between the two stocks.